LIB Therapeutics has passed another milestone on its path to launching a challenger to cholesterol drugs sold by Amgen, Regeneron and Sanofi. In the latest phase 3 readout, the private biotech’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback